Last reviewed · How we verify
HSK44459
At a glance
| Generic name | HSK44459 |
|---|---|
| Sponsor | Xizang Haisco Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study for HSK44459 in Participants With Atopic Dermatitis (PHASE2)
- A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis (PHASE2)
- A Long-term Study of HSK44459 Tablets in Participants With Bechet's Disease (PHASE2)
- Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF) (PHASE2)
- Evaluating the Efficacy and Safety of of HSK44459 in Patients With Behçet's Disease (PHASE2)
- A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK44459 in Healthy Subjects (PHASE1)
- Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HSK44459 CI brief — competitive landscape report
- HSK44459 updates RSS · CI watch RSS
- Xizang Haisco Pharmaceutical Co., Ltd portfolio CI